Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Pramoda Challagundla, Celina Ledesma, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Paolo Anderlini, MD, Qaiser Bashir, MD, Betul Oran, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD, Jeffrey L. Jorgensen, MD, PhD

Blood (2013) 122 (21): 3349.

https://doi.org/10.1182/blood.V122.21.3349.3349

Published: 2013

Journal Articles

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Zijun Y Xu-Monette, MD, Gabriela Rondon, MD, Rosamar Valverde, MD, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Paolo Anderlini, MD, Ahmed Sairah, MD, Chitra M. Hosing, MD, Uday R Popat, MD, Partow Kebriaei, MD, Luis E Fayad, Jason R. Westin, MD, Francesco Turturro, MD, L. Jeffrey Medeiros, MD, Richard E Champlin, MD, Ken H. Young, MD, PhD

Blood (2013) 122 (21): 3350.

https://doi.org/10.1182/blood.V122.21.3350.3350

Published: 2013

Journal Articles

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Paolo Anderlini, MD, Rima M. Saliba, Ph.D., Celina Ledesma, B.S., Christina M Chancoco, Tamera Alexander, P.A., Amin Alousi, MD, Chitra M. Hosing, MD, Issa Khouri, MD, Yago Nieto, M.D., Ph.D., Uday R Popat, MD, Elizabeth J Shpall, MD, Michelle A. Fanale, M.D., Yasuhiro Oki, MD, Jorge E Romaguera, MD, Sattva Neelapu, MD, Anas Younes, M.D., Richard E Champlin, MD

Blood (2013) 122 (21): 410.

https://doi.org/10.1182/blood.V122.21.410.410

Published: 2013

Journal Articles

Early Mixed T-Lymphocyte and Myeloid Chimerism Is Predictive of Disease Recurrence Following Allogeneic Stem Cell Transplantation for AML/MDS.

Hans C. Lee, MD, Rima M. Saliba, Ph.D., Gabriela Rondon, MD, Julianne Chen, Yasmeen Charafeddine, L. Jeffrey Medeiros, MD, Marcos De Lima, MD, Borje S Andersson, MD, PhD, Partow Kebriaei, M.D., Betul Oran, MD, MS, Richard E. Champlin

Blood (2012) 120 (21): 3075.

https://doi.org/10.1182/blood.V120.21.3075.3075

Published: 2012

Journal Articles

Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.

Sairah Ahmed, MD, Rima M Saliba, Ph.D, Marcos De Lima, MD, Gabriela Rondon, MD, Partow Kebriaei, MD, Tobi DeAnn Fisher, MPAS, Elias Jabbour, MD, Julianne Chen, Hagop Kantarjian, MD, Paolo Anderlini, MD, Amin M Alousi, MD, Chitra M Hosing, MD, Borje Andersson, MD, PhD, Roy B. Jones, MD, Ph.D., Muzaffar H. Qazilbash, MD, Elizabeth J. Shpall, MD, Sergio Giralt, MD, Richard E Champlin, MD

Blood (2012) 120 (21): 3129.

https://doi.org/10.1182/blood.V120.21.3129.3129

Published: 2012

Journal Articles

Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Amir Hamdi, M.D., LM Poon, M.D., Rima M. Saliba, Ph.D., Gabriela Rondon, M.D., Celina Ledesma, Muzaffar Qazilbash, M.D., Chitra M. Hosing, M.D., Roy B. Jones, MD, Ph.D., Uday R. Popat, M.D., Nieto, M.D., Ph.D., Amin M. Alousi, M.D., Stefan O. Ciurea, Elizabeth J. Shpall, M.D., Richard E. Champlin, Partow Kebriaei, M.D.

Blood (2012) 120 (21): 4215.

https://doi.org/10.1182/blood.V120.21.4215.4215

Published: 2012

Journal Articles

Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Marcos de Lima, MD, Simrit Parmar, M.D., Julianne J Chen, Sergio A Giralt, MD, Gabriela Rondon, MD, Uday R. Popat, M.D., Amin M. Alousi, M.D., Hans C. Lee, MD, Glenda G Woodworth, RN, Chitra M Hosing, MD, Elizabeth J. Shpall, Partow Kebriaei, M.D., Guillermo garcia Manero, MD, Richard E. Champlin, Rima M. Saliba, Ph.D.

Blood (2012) 120 (21): 742.

https://doi.org/10.1182/blood.V120.21.742.742

Published: 2012

Journal Articles

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

Lisa Zipp, MS, Rima M Saliba, Ph.D., Rosamar Valverde, Grace-Julia Okoroji, Martin Korbling, MD, Barry I Samuels, MD, Lynne V. Abruzzo, MD, PhD, Amin M Alousi, MD, Borje S Andersson, MD, PhD, Chitra M Hosing, MD, Bill Erwin, MS, Paolo Anderlini, MD, Uday R Popat, MD, Partow Kebriaei, Homer A Macapinlac, MD, Richard Champlin, MD, Issa F. Khouri, MD

Blood (2011) 118 (21): 2005.

https://doi.org/10.1182/blood.V118.21.2005.2005

Published: 2011

Journal Articles

Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization,

Rima M Saliba, Ph.D., Alexandre Chiattone, MD, Alejandro Majlis, MD, Viviane C. Chiattone, RN, Gabriela Rondon, MD, Araci M. Sakashita, MD, Nelson Hamerschlak, MD, Jose Mauro Kutner, MD, PhD, Elizabeth J Shpall, MD, Paolo Anderlini, MD, Issa Khouri, MD, Muzaffar H Qazilbash, MD, Uday Popat, M.D., Richard Champlin, MD, Chitra M Hosing, MD, Marcos De Lima, MD

Blood (2011) 118 (21): 4058.

https://doi.org/10.1182/blood.V118.21.4058.4058

Published: 2011

Journal Articles

12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years,

Zaher I Chakhachiro, MD, Rima M Saliba, Ph.D., Grace-Julia Okoroji, Martin Korbling, MD, Amin M Alousi, MD, Chitra M Hosing, MD, Marcos De Lima, MD, Paolo Anderlini, MD, Uday Popat, M.D., Barry I Samuels, MD, L. Jeffrey Medeiros, MD, Carlos E. Bueso-Ramos, MD, PhD, Richard Champlin, MD, Issa F Khouri, MD

Blood (2011) 118 (21): 4138.

https://doi.org/10.1182/blood.V118.21.4138.4138

Published: 2011

Journal Articles

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Blood (2011) 118 (21): 662.

https://doi.org/10.1182/blood.V118.21.662.662

Published: 2011

Journal Articles

Outcomes of Allogeneic Stem Cell Transplant in Patients with Myeloid Leukemias Over 65 Years of Age. Rationale for Aggressive Therapy with Curative Intent.

Sergio Giralt, Rima M Saliba, Ph.D, Gabriela Rondon, Leandro de Padua Silva, Amin M. Alousi, Uday Popat, Marco De Lima, Borje Andersson, Partow Kebriae, MD, Paolo Anderlini, Chitra Hosing, MD, Roy Jones, Elizabeth J. Shpall, MD, Richard E. Champlin, Issa F. Khouri

Blood (2008) 112 (11): 2153.

https://doi.org/10.1182/blood.V112.11.2153.2153

Published: 2008

Journal Articles

Regulatory and Naïve T Cells in Unmanipulated Donor Grafts Are Not Associated with Acute Graft Vs Host Disease in Matched Sibling Transplants for AML

Jahan S. Khalili, Rima M Saliba, Ph.D., Lisa St. John, Ph.D., Amin Alousi, M.D., Eric D. Wieder, Ph.D., Marcos De Lima, M.D., Richard Champlin, M.D., Jeffrey J. Molldrem, M.D., E. J. Shpall, M.D., John McMannis, Ph.D., Krishna V. Komanduri, M.D.

Blood (2008) 112 (11): 719.

https://doi.org/10.1182/blood.V112.11.719.719

Published: 2008

Journal Articles

Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.

Gaurav C. Parikh, MD, MPH (2nd Year), Rima M. Saliba, Ph.D., Amit Lahoti, MD, Chitra Hosing, MD, Floralyn Mendoza, BS, Suhail R. Qureshi, MD, Donna M. Weber, MD, BS, Michael Wang, MD, MS, Uday Popat, MD, Amin Alousi, MD, Richard E. Champlin, MD, Sergio A. Giralt, MD, Muzaffar H. Qazilbash, MD

Blood (2007) 110 (11): 5126.

https://doi.org/10.1182/blood.V110.11.5126.5126

Published: 2007

NARROW

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Outcomes Following Autologous Stem Cell Transplantation (ASCT) In Patients With Germinal Center B (GCB) and Non-GCB Cell-Like Diffuse Large B Cell Lymphomas (DLBCL) According To Conditioning With BEAM-Rituximab (Standard vs. High-Dose) Vs. BEAM/Yttrium-90 Ibritumomab Tiuxetan ( 90 YIT)

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)

Early Mixed T-Lymphocyte and Myeloid Chimerism Is Predictive of Disease Recurrence Following Allogeneic Stem Cell Transplantation for AML/MDS.

Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.

Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin ® ) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization,

12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years,

Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90 yttrium Ibritumomab Tiuxetan ( 90 YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Outcomes of Allogeneic Stem Cell Transplant in Patients with Myeloid Leukemias Over 65 Years of Age. Rationale for Aggressive Therapy with Curative Intent.

Regulatory and Naïve T Cells in Unmanipulated Donor Grafts Are Not Associated with Acute Graft Vs Host Disease in Matched Sibling Transplants for AML

Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only